| Editor's Note: The Fierce PM Tracker will not publish Monday, May 26, in observance of Memorial Day. We’ll be back in your inbox on Tuesday, May 27. |
Today’s Big NewsMay 23, 2025 |
|
Thursday, May 29, 2025 | 11am ET / 8am PT While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. It is more important than ever to implement strategies and solutions for maximizing efficiencies throughout the drug development process. Join us to learn more. 
|
|
| By Fraiser Kansteiner In the ASCENT-03 trial, Gilead's Trodelvy bested chemotherapy at extending the time before disease worsening or death in certain patients with previously untreated metastatic triple-negative breast cancer. The results help pad the case for Trodelvy in first-line breast cancer following positive results for a Trodelvy-Keytruda cocktail in a similar indication last month. |
|
|
|
By Nick Paul Taylor Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair analysts' belief the candidate has a “best-in-disease profile.” |
By Zoey Becker Itovebi, when added to Pfizer’s Ibrance and AstraZeneca’s Faslodex, cut the risk of death by 33% in a phase 3 trial of certain breast cancer patients. |
By Angus Liu Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. But the pair’s success leaves room for improvement for future contenders. |
|
Thursday, June 5, 2025 | 11am ET / 8am PT Off-target binding can be a significant hurdle in the development of antibody-based therapies, with limitations of conventional screening methods being a key factor. Join our webinar to learn more about the latest approaches to specificity profiling. Register now. 
|
|
By Nick Paul Taylor Genmab has shared the first data on rinatabart sesutecan in advanced endometrial cancer. The biotech reported a 50% unconfirmed response rate, beating the expectations of William Blair analysts to boost confidence in the program ahead of its move into phase 3. |
By Conor Hale Roche tapped a subsidiary of the MIT and Harvard research center to apply sequencing-by-expansion tech in screening newborns and their parents. |
By Darren Incorvaia,Zoey Becker Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—is heading for the exit. |
By Fraiser Kansteiner Sanofi has officially opened its swanky new offices in Morristown, New Jersey, where nearly 2,000 employees recently relocated. The drugmaker invested $130 million in the new facility, which features flexible workspaces, wellness rooms, a public-facing restaurant and “the largest outdoor terrace space" in the state. |
By Gabrielle Masson Earlier this year, Cullinan said its lead candidate hit the bull's-eye in a midstage lung cancer cancer trial but stayed mum on the details. Now, the biotech is revealing the results that have prompted the company and partner Taiho Oncology to pursue an accelerated approval. |
By Kevin Dunleavy Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended GSK's Blenrep for approval for patients with relapsed or refractory multiple myeloma. The nod was one of several decisions made by the committee this week. |
By Noah Tong,Dave Muoio Recent lawsuits from nonprofits, state attorneys general, unions and local governments say the reorganizations and reductions in force imposed on federal agencies like the HHS were unconstitutional. |
By Andrea Park AstraZeneca is putting the pedal to the metal to drive up early detection of prostate cancer. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma breaks down President Donald Trump’s executive order targeting drug prices and what it could mean for the industry as broader policy shifts unfold. |
|
|---|
|
|
|
Wednesday, June 11, 2025 | 11am ET / 8am PT Join us for a deep dive into the strategies and best practices for maximizing valuation by improving productivity in modern clinical trials. We'll discuss key ways to achieve tangible productivity gains, accelerate timelines, and avoid costly protocol amendments or clinical failures. Register now to learn expert tips for maximizing efficiency and effectiveness. 
|
|
Whitepaper Don’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
Whitepaper Learn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
Whitepaper We interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
+(2)+(1).png)
